Whether Abatacept has entered the scope of medical insurance and the reimbursement policy

Abatacept is a recombinant fusion protein that regulates immune responses mainly by inhibiting T cell co-stimulatory signals. It is widely used to treat moderate to severe active rheumatoid arthritis (RA), ankylosing spondylitis and other autoimmune diseases. Its mechanism of action is unique and different from traditional immunosuppressants, so it is often used clinically for patients who are ineffective or poorly tolerated by traditional treatments.

At present, abatacept has been launched in the country, but it has not yet been included in the medical insurance coverage. This means that patients have to pay out-of-pocket to purchase the drug in the country, and the cost burden is high. The domestic price is about six to seven thousand yuan per box. The specific price may vary depending on the region, hospital or pharmacy. Patients should consult local regular medical institutions to obtain accurate price information before purchasing.

In overseas markets, the price of abatacept's original drug is relatively low in countries such as Türkiye. Each box sells for about more than 5,000 yuan, which is also the version of the original drug. Although overseas prices are slightly lower, domestic patients still need to purchase them through formal overseas medical channels, and pay attention to the storage conditions and legality of the drugs during transportation and use to ensure efficacy and safety.

Generally speaking, abatacept has not been included in medical insurance in the country, and patients need to bear the cost of the drug themselves. When purchasing, you should give priority to regular hospital pharmacies or trustworthy overseas channels, and use it rationally under the guidance of professional doctors. In the future, with the update of domestic medical insurance policies and the expansion of the drug market, abatacept's accessibility and economic burden are expected to further improve, providing patients with autoimmune diseases with more convenient treatment options.

Reference link:https://www.drugs.com